Raymond James Financial Inc. Makes New $887,000 Investment in MiMedx Group, Inc. (NASDAQ:MDXG)

Raymond James Financial Inc. acquired a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 92,207 shares of the company's stock, valued at approximately $887,000. Raymond James Financial Inc. owned 0.06% of MiMedx Group as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MDXG. Van ECK Associates Corp bought a new position in shares of MiMedx Group during the 4th quarter valued at $40,000. Point72 DIFC Ltd lifted its holdings in MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after acquiring an additional 4,275 shares during the period. Orion Capital Management LLC lifted its holdings in MiMedx Group by 46.3% in the third quarter. Orion Capital Management LLC now owns 11,700 shares of the company's stock valued at $69,000 after acquiring an additional 3,700 shares during the period. SkyView Investment Advisors LLC boosted its position in MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company's stock worth $77,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Savant Capital LLC bought a new stake in shares of MiMedx Group during the 4th quarter valued at about $100,000. Hedge funds and other institutional investors own 79.15% of the company's stock.

Insider Activity

In other MiMedx Group news, CAO William Frank Iv Hulse sold 54,596 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the sale, the chief accounting officer now owns 440,178 shares in the company, valued at $3,473,004.42. The trade was a 11.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. The trade was a 1.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 144,018 shares of company stock worth $1,130,312 over the last ninety days. Corporate insiders own 1.30% of the company's stock.

Remove Ads

MiMedx Group Stock Performance

Shares of NASDAQ MDXG traded up $0.30 during trading on Wednesday, hitting $7.16. The company had a trading volume of 864,454 shares, compared to its average volume of 697,782. MiMedx Group, Inc. has a 12 month low of $5.21 and a 12 month high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The firm has a market capitalization of $1.06 billion, a P/E ratio of 13.02 and a beta of 1.74. The stock has a 50 day simple moving average of $7.92 and a 200 day simple moving average of $7.97.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.07. The firm had revenue of $92.91 million during the quarter, compared to analysts' expectations of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. As a group, analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

MDXG has been the topic of several recent research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com upgraded shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 4th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.